Publication

Video

Priority Report
Management of Diarrhea in Breast Cancer
Volume 1
Issue 1

Dr. Velez on Managing Neratinib-Associated Diarrhea in HER2+ Breast Cancer

Michel Velez, MD, medical oncologist at Holy Cross Hospital, discusses the management of neratinib (Nerlynx)-associated diarrhea in patients with early-stage HER2-positive breast cancer.

Michel Velez, MD, medical oncologist at Holy Cross Hospital, discusses the management of neratinib (Nerlynx)-associated diarrhea in patients with early-stage HER2-positive breast cancer.

The incidence of grade 3 diarrhea was approximately 40% in the phase III ExteNET trial; however, diarrhea was managed reactively and not proactively, says Velez. In the phase II CONTROL trial, prophylactic intervention was used to reduce the rate of diarrhea that had been observed in the ExteNET trial.

Patients in the trial received neratinib and were randomized to 1 of 3 arms: loperamide only, the combination of budesonide and colestipol, or dose-escalated neratinib. Both the loperamide and combination arms showed a reduction in the incidence of grade 3 diarrhea. However, the combination resulted in a 50% reduction in the rate of grade 3 diarrhea, says Velez.

Among the 3 arms, the dose escalation arm appears to be the most promising. Dose-escalated therapy is not a new concept; it has shown much success when used in other cancer types, adds Velez. However, these data have yet to be reported from the third arm of the CONTROL trial. Ultimately, there are several options for managing diarrhea that can be used to get patients through the full course of neratinib therapy.

Related Videos
Dana Zakalik, MD
Alberto Montero, MD, MBA, CPHQ
Jairam Krishnamurthy, MD, FACP
Deena Mary Atieh Graham, MD
Sheldon M. Feldman, MD
Sheldon M. Feldman, MD
David Rimm, MD, PhD
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.
In this episode of OncChats: Empowering Community Cancer Care, Dr. Woodworth sheds light on the “Road to Recovery” survivorship program at Henry Mayo, which supports cancer survivors by providing them with fitness, education, and mental health resources, and underscores the importance of mentorship programs for community providers to ensure equitable cancer care.
In this episode of OncChats: Empowering Community Cancer Care, Drs Woodworth and Rai, discuss their collaborative approach to cancer screening, emphasizing the importance of community efforts and individual assessments in integrating genetic testing and screenings into routine practice.